title: Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
abstract: OBJECTIVE
  Adjuvant chemotherapy is recommended for stage III colon cancer. The aim of this study was to identify important prognostic factors among patients with colon cancer receiving adjuvant 5-FU-based treatment.
  
  
  METHODS
  Data sets of 855 colon cancer patients treated between 1992 and 1999 within a multicenter adjuvant trial comparing 5-FU modulation with folinic acid or interfereron-alpha were examined. Backward elimination in a proportional hazards model was used to identify prognostically relevant clinical and pathological factors.
  
  
  RESULTS
  Tumor recurrence (p<0.001), duration of adjuvant treatment (p<0.001), tumor substage (p=0.004), age (p=0.005), grading (p=0.016), treatment-related toxicity (p=0.021), and treatment (p=0.031) were identified in descending order of importance as prognostic factors for overall survival.
  
  
  CONCLUSIONS
  Adjuvant 5-FU-based treatment should be performed for at least 6months with a stepwise adjustment of 5-FU doses until toxicity >WHO II. Substages should be reported separately and used for stratification in future trials due to their broad variation in outcome. In the future, this may result in adjuvant treatment of stage III colon cancer adjusted for the risk of substages.
authors.affiliation: Clinic of General, Visceral, and Transplantation Surgery, University of Ulm, Steinhoevelstrasse 9, 89075 Ulm, Germany. marko.kornmann@uniklinik-ulm.de
authors.forename: M
authors.initials: M
authors.lastname: Kornmann
authors.forename: A
authors.initials: A
authors.lastname: Formentini
authors.forename: C
authors.initials: C
authors.lastname: Ette
authors.forename: D
authors.initials: D
authors.lastname: Henne-Bruns
authors.forename: M
authors.initials: M
authors.lastname: Kron
authors.forename: S
authors.initials: S
authors.lastname: Sander
authors.forename: W
authors.initials: W
authors.lastname: Baumann
authors.forename: E-D
authors.initials: ED
authors.lastname: Kreuser
authors.forename: L
authors.initials: L
authors.lastname: Staib
authors.forename: K H
authors.initials: KH
authors.lastname: Link
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D015994:Incidence; D016898:Interferon-alpha / Q000627:therapeutic use; D002955:Leucovorin / Q000627:therapeutic use; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D013997:Time Factors; D014803:Vitamin B Complex / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D007155:Immunologic Factors; D016898:Interferon-alpha; D014803:Vitamin B Complex; D002955:Leucovorin; D005472:Fluorouracil